TWIICE One powered exoskeleton: effect of design improvements on usability in daily life as measured by the performance in the CYBATHLON race.

Exoskeleton training Gait Overground walking Powered exoskeleton Powered gait orthosis Spinal cord injury Wearable robotics

Journal

Journal of neuroengineering and rehabilitation
ISSN: 1743-0003
Titre abrégé: J Neuroeng Rehabil
Pays: England
ID NLM: 101232233

Informations de publication

Date de publication:
27 06 2022
Historique:
received: 26 10 2021
accepted: 17 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 30 6 2022
Statut: epublish

Résumé

Spinal cord injury leading to paraplegia affects the mobility and physiological well-being of one in a thousand people. Powered exoskeletons can temporarily restore the ability to walk. Their relevance in daily life is still limited because of low performance beyond ground that is even. CYBATHLON is an international competition promoting improvements in assistive technology. In this article, we present the latest design and results of testing of TWIICE One version 2018, one of the competing devices in the 2020 race. A person with a motor-complete spinal cord injury at thoracic level T10 participated as race pilot. Training ahead of the race took place over one week at a rate of 2 h per day. The time to perform each of the seven tasks of the competition was recorded together with the number of repetitions. Performance is compared over the training period and against the 2016 race results. Progression was observed in all tasks and accounted for by both user training and technology improvements. Final competition rank was second out of seven participating teams, with a record time of 4'40". This represents an average improvement of 40% with respect to comparable obstacles of the 2016 race, explaining the two ranks of improvement since then. These results help understand which features had a positive impact on the real-life performance of the device. Understanding how design affects performance is key information to create devices that really improve the life of people living with paraplegia.

Sections du résumé

BACKGROUND
Spinal cord injury leading to paraplegia affects the mobility and physiological well-being of one in a thousand people. Powered exoskeletons can temporarily restore the ability to walk. Their relevance in daily life is still limited because of low performance beyond ground that is even. CYBATHLON is an international competition promoting improvements in assistive technology. In this article, we present the latest design and results of testing of TWIICE One version 2018, one of the competing devices in the 2020 race.
METHODS
A person with a motor-complete spinal cord injury at thoracic level T10 participated as race pilot. Training ahead of the race took place over one week at a rate of 2 h per day. The time to perform each of the seven tasks of the competition was recorded together with the number of repetitions. Performance is compared over the training period and against the 2016 race results.
RESULTS
Progression was observed in all tasks and accounted for by both user training and technology improvements. Final competition rank was second out of seven participating teams, with a record time of 4'40". This represents an average improvement of 40% with respect to comparable obstacles of the 2016 race, explaining the two ranks of improvement since then.
CONCLUSION
These results help understand which features had a positive impact on the real-life performance of the device. Understanding how design affects performance is key information to create devices that really improve the life of people living with paraplegia.

Identifiants

pubmed: 35761399
doi: 10.1186/s12984-022-01028-0
pii: 10.1186/s12984-022-01028-0
pmc: PMC9238043
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

63

Informations de copyright

© 2022. The Author(s).

Références

Med Biol Eng. 1974 Jan;12(1):66-80
pubmed: 4465554
Med Devices (Auckl). 2017 May 09;10:89-107
pubmed: 28533700
Qual Life Res. 2017 Nov;26(11):3143-3155
pubmed: 28712004
Med Devices (Auckl). 2016 Mar 22;9:455-66
pubmed: 27042146
J Rehabil Med. 2017 Jan 19;49(1):84-87
pubmed: 27973679
Sci Robot. 2018 Apr 25;3(17):
pubmed: 33141744
J Spinal Cord Med. 2021 Jun 01;:1-6
pubmed: 34062111
Disabil Rehabil Assist Technol. 2019 Feb;14(2):138-145
pubmed: 29256640
Top Spinal Cord Inj Rehabil. 2018 Winter;24(1):78-85
pubmed: 29434463
IEEE Int Conf Rehabil Robot. 2017 Jul;2017:1639-1645
pubmed: 28814055
J Neurol Phys Ther. 2018 Oct;42(4):256-267
pubmed: 30199518
Top Spinal Cord Inj Rehabil. 2015 Spring;21(2):110-21
pubmed: 26364280
Disabil Rehabil. 2021 Jul;43(14):1982-1988
pubmed: 31724882
J Neuroeng Rehabil. 2018 Mar 13;15(1):18
pubmed: 29534730
Top Spinal Cord Inj Rehabil. 2017 Summer;23(3):245-255
pubmed: 29339900
Am J Phys Med Rehabil. 2012 Nov;91(11):911-21
pubmed: 23085703
Top Spinal Cord Inj Rehabil. 2015 Spring;21(2):100-9
pubmed: 26364279
Proc Inst Mech Eng H. 2007 Aug;221(6):629-39
pubmed: 17937202
Top Spinal Cord Inj Rehabil. 2015 Spring;21(2):93-9
pubmed: 26364278
Am J Phys Med Rehabil. 2007 May;86(5):387-96
pubmed: 17449983
Front Neurosci. 2017 Dec 12;11:699
pubmed: 29311780
Prosthet Orthot Int. 2012 Jun;36(2):239-46
pubmed: 22368113
Disabil Rehabil. 2019 Mar;41(5):560-563
pubmed: 29110547
Front Neurosci. 2018 Jan 11;11:756
pubmed: 29375294
Sci Rep. 2020 Sep 24;10(1):15600
pubmed: 32973244
J Neuroeng Rehabil. 2017 Nov 09;14(1):112
pubmed: 29121967
J Neuroeng Rehabil. 2016 May 31;13(1):49
pubmed: 27246601
Arch Phys Med Rehabil. 2021 Feb;102(2):331-337
pubmed: 31228407
Disabil Health J. 2018 Jul;11(3):478-485
pubmed: 29500092
Front Robot AI. 2020 Aug 04;7:93
pubmed: 33501260
Top Spinal Cord Inj Rehabil. 2018 Fall;24(4):336-342
pubmed: 30459496
Eur J Phys Rehabil Med. 2019 Apr;55(2):209-216
pubmed: 30156088

Auteurs

Tristan Vouga (T)

TWIICE SA, Lausanne, Switzerland. tristan.vouga@twiice.ch.

Jemina Fasola (J)

TWIICE SA, Lausanne, Switzerland.

Romain Baud (R)

Sonceboz SA, Sonceboz-Sombeval, Switzerland.

Ali Reza Manzoori (AR)

Biorobotics Laboratory (BioRob), EPFL, Lausanne, Switzerland.

Julien Pache (J)

TWIICE SA, Lausanne, Switzerland.

Mohamed Bouri (M)

Biorobotics Laboratory (BioRob), EPFL, Lausanne, Switzerland.
Translational Neural Engineering Laboratory (TNE), EPFL, Campus Biotech, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH